Citations (55)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (14)
Krisztián Gáspár, L. Hunor Gergely, Balázs Jenei, Norbert Wikonkál, Ágnes Kinyó, Andrea Szegedi, éva Remenyik, Norbert Kiss, Xiang Jin, Miklós Sárdy, Zsuzsanna Beretzky, Márta Péntek, László Gulácsi, András Bánvölgyi, Valentin Brodszky & Fanni Rencz. (2022) Resource utilization, work productivity and costs in patients with hidradenitis suppurativa: a cost-of-illness study. Expert Review of Pharmacoeconomics & Outcomes Research 22:3, pages 399-408.
Read now
Read now
Deepak M. W. Balak, Jose-Manuel Carrascosa, Stamatis Gregoriou, Piergiacomo Calzavara-Pinton, Anthony Bewley, Joana Antunes, Martin E. Nyeland, Marta G. Viola, Laura M. Sawyer & Lidia Becla. (2021) Cost per PASI-75 responder of calcipotriol plus betamethasone dipropionate cutaneous foam versus nonbiologic systemic therapies for the treatment of plaque psoriasis in seven European countries. Journal of Dermatological Treatment 32:7, pages 701-708.
Read now
Read now
Mathias Tiedemann Svendsen, Steven R. Feldman, Sylvia Naiga Tiedemann, Anne Sofie Stochholm Sørensen, Cecilie Marie Ringgaard Rivas & Klaus Ejner Andersen. (2021) Dermatology nurses view on factors related to Danish psoriasis patients’ adherence to topical drugs: a focus group study. Journal of Dermatological Treatment 32:5, pages 497-502.
Read now
Read now
V. Brodszky, B. Tamási, K. Hajdu, M. Péntek, A. Szegedi, M. Sárdy, Z. Bata-Csörgő, Á. Kinyó, L. Gulácsi & F. Rencz. (2021) Disease burden of patients with pemphigus from a societal perspective. Expert Review of Pharmacoeconomics & Outcomes Research 21:1, pages 77-86.
Read now
Read now
Sascha Gerdes, Andreas Körber, Mona Biermann, Claudia Karnthaler & Maximilian Reinhardt. (2020) Absolute and relative psoriasis area and severity index (PASI) treatment goals and their association with health-related quality of life. Journal of Dermatological Treatment 31:5, pages 470-475.
Read now
Read now
Erica B. Lee, Deeti J. Pithadia, Kelly A. Reynolds & Jashin J. Wu. (2019) Institute for clinical and economic review (ICER) psoriasis update 2018: what it means for dermatologists treating moderate-to-severe plaque psoriasis. Journal of Dermatological Treatment 30:8, pages 772-774.
Read now
Read now
Mwangi J. Murage, David M. Kern, Lawrence Chang, Kalyani Sonawane, William N. Malatestinic, Ralph A. Quimbo, Steven R. Feldman, Talia M. Muram & Andre B. Araujo. (2019) Treatment patterns among patients with psoriasis using a large national payer database in the United States: a retrospective study. Journal of Medical Economics 22:1, pages 53-62.
Read now
Read now
Luca Degli Esposti, Valentina Perrone, Diego Sangiorgi, Stefano Buda, Margherita Andretta, Maurizio Rossini & Giampiero Girolomoni. (2018) Analysis of drug utilization and health care resource consumption in patients with psoriasis and psoriatic arthritis before and after treatment with biological therapies. Biologics: Targets and Therapy 12, pages 151-158.
Read now
Read now
Laura Sawyer, Iain Fotheringham, Emily Wright, Najeeda Yasmeen, Carl Gibbons & Anders Holmen Møller. (2018) The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis. Journal of Dermatological Treatment 29:6, pages 557-568.
Read now
Read now
G. Carretero, L. Puig, J. M. Carrascosa, L. Ferrándiz, R. Ruiz-Villaverde, P. de la Cueva, I. Belinchon, E. Vilarrasa, R. del Rio, J. L. Sánchez-Carazo, A. López-Ferrer, F. Peral, S. Armesto, N. Eiris, J. Mitxelena, J. Vilar-Alejo, M. A. Martin & C. Soria. (2018) Redefining the therapeutic objective in psoriatic patients candidates for biological therapy. Journal of Dermatological Treatment 29:4, pages 334-346.
Read now
Read now
Francesca Guerriero, Valentina Orlando, Valeria Marina Monetti, Veronica Russo & Enrica Menditto. (2017) Biological therapy utilization, switching, and cost among patients with psoriasis: retrospective analysis of administrative databases in Southern Italy. ClinicoEconomics and Outcomes Research 9, pages 741-748.
Read now
Read now
Valentina Perrone, Diego Sangiorgi, Stefano Buda & Luca Degli Esposti. (2017) Topical medication utilization and health resources consumption in adult patients affected by psoriasis: findings from the analysis of administrative databases of local health units. ClinicoEconomics and Outcomes Research 9, pages 181-188.
Read now
Read now
Kyriakos Souliotis, Christina Golna, Chara Kani & Panagiota Litsa. (2016) Reducing patient copayment levels for topical and systemic treatments in plaque psoriasis as a case for evidence-based, sustainable pharmaceutical policy change in Greece. Journal of Medical Economics 19:11, pages 1021-1026.
Read now
Read now
Nicole C. Rouse, Michael E. Farhangian, Brooke Wehausen & Steven R. Feldman. (2015) The cost-effectiveness of ustekinumab for moderate-to-severe psoriasis. Expert Review of Pharmacoeconomics & Outcomes Research 15:6, pages 877-884.
Read now
Read now
Articles from other publishers (41)
Xia Zhu, Qingqing Xu, Zhaoyang Liu, Zhiqiang Cao, Mingming Li, Jingjing Wei, Lingyun Du, Changyu Han & Chunhong Zhang. (2024) Qingre Lishi Decoction ameliorates imiquimod-induced psoriasis-like skin lesions in SKH-1 mice by regulating the Treg-DC-Th17 axis and inhibiting MAPK-mediated DC maturation. Journal of Ethnopharmacology 318, pages 116931.
Crossref
Crossref
Yazed AlRuthia, Almaha H. Alfakhri, Ibtisam Alharbi, Fadi Ali Alghamdi, Miteb A. Alanazi, Abdullah Abdulrahman Alrabiah, Anwar Abdulrazzag Alsouan, Abdulrahman Abdullah Alshaikh & Majed Ali Almasaoud. (2023) Comparative effectiveness and cost evaluation of Risankizumab and Adalimumab in the management of psoriasis: a real-world study in Saudi Arabia. Cost Effectiveness and Resource Allocation 21:1.
Crossref
Crossref
Congjun Jiang, Yu Du, Xiaoyan Liu, Jingjing Wang, Cuizhu Ge, Jingyue Xu, Shuoxiong Wang, Benke Li, Gege Zhu, Wanlu Zhang, Qiaoxiao Qian, Chi Ma, Xiangyang Zhu, Yifan Zhan & Yongmin Yang. (2023) Safety, tolerability, pharmacokinetics and efficacy of HB0017, a humanized monoclonal antibody that targets interleukin-17A, in healthy participants and patients with moderate-to-severe plaque psoriasis. British Journal of Dermatology.
Crossref
Crossref
Niels Hilhorst, Erin Roman, Joke Borzée, Elfie Deprez, Isabelle Hoorens, Brecht Cardoen, Filip Roodhooft & Jo Lambert. (2023) Value in psoriasis (IRIS) trial: implementing value-based healthcare in psoriasis management – a 1-year prospective clinical study to evaluate feasibility and value creation. BMJ Open 13:5, pages e067504.
Crossref
Crossref
Kai Huang, Xian Wu, Yixin Li, Chengzhi Lv, Yangtian Yan, Zhe Wu, Mi Zhang, Weihong Huang, Zixi Jiang, Kun Hu, Mingjia Li, Juan Su, Wu Zhu, Fangfang Li, Mingliang Chen, Jing Chen, Yongjian Li, Mei Zeng, Jianjian Zhu, Duling Cao, Xing Huang, Lei Huang, Xing Hu, Zeyu Chen, Jian Kang, Lei Yuan, Chengji Huang, Rui Guo, Alexander Navarini, Yehong Kuang, Xiang Chen & Shuang Zhao. (2023) Artificial Intelligence–Based Psoriasis Severity Assessment: Real-world Study and Application. Journal of Medical Internet Research 25, pages e44932.
Crossref
Crossref
Richard Perry, Abigail J. Beveridge, Amy J. Sears & Elisabeth R. Rasmussen. (2023) Expert Consensus on Real-World Use and Consumption Patterns of a Fixed-Dose Combination Foam for Psoriasis as a Reactive Management (RM) and Proactive Management (PAM) Regimen. Advances in Therapy 40:3, pages 1062-1073.
Crossref
Crossref
Congjun Jiang, Huan Zhou, Wanlu Zhang, Yu Xia, Baiyong Li, Xiang Ni, Guoqin Wang, Wenhui Zhang, Benchao Chen, Zhimei He, Min Zhang, Rui Chen, Hongzhong Jin & Liehua Deng. (2022) Efficacy, Safety and Pharmacokinetics of IL-17 Monoclonal Antibody Injection (AK111) in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blinded, Placebo-Controlled Phase Ib Multidose Escalation Clinical Study. Dermatology and Therapy 13:2, pages 555-567.
Crossref
Crossref
Alexandr Chernov, Daria Kilina, Tatiana Smirnova & Elvira Galimova. (2022) Pharmacogenetic Study of the Impact of ABCB1 Single Nucleotide Polymorphisms on the Response to Cyclosporine in Psoriasis Patients. Pharmaceutics 14:11, pages 2441.
Crossref
Crossref
Christopher Tehlirian, Ravi Shankar P. Singh, Vivek Pradhan, Erika S. Roberts, Sanela Tarabar, Elena Peeva, Michael S. Vincent & Jeremy D. Gale. (2022) Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study. Journal of the American Academy of Dermatology 87:2, pages 333-342.
Crossref
Crossref
Trinidad Montero-Vílchez, Manuel Sánchez-Díaz, Antonio Martínez-López & Salvador Arias-Santiago. 2022. Health-Related Quality of Life - Measurement Tools, Predictors and Modifiers. Health-Related Quality of Life - Measurement Tools, Predictors and Modifiers.
Tomoyuki Hioki, Mayumi Komine & Mamitaro Ohtsuki. (2022) Diagnosis and Intervention in Early Psoriatic Arthritis. Journal of Clinical Medicine 11:7, pages 2051.
Crossref
Crossref
Alexey A. Kubanov & Elena V. Bogdanova. (2022) Epidemiology of psoriasis in the Russian Federation according to the patient registry. Vestnik dermatologii i venerologii 98:1, pages 33-41.
Crossref
Crossref
Trinidad Montero-Vilchez, Antonio Martinez-Lopez, Alvaro Sierra-Sanchez, Miguel Soler-Gongora, Eladio Jimenez-Mejias, Alejandro Molina-Leyva, Agustin Buendia-Eisman & Salvador Arias-Santiago. (2021) Erythema Increase Predicts Psoriasis Improvement after Phototherapy. Journal of Clinical Medicine 10:17, pages 3897.
Crossref
Crossref
Henrike Häbel, Björn Wettermark, David Hägg, Reginald Villacorta, E.Christina M. Wennerström & Marie Linder. (2021) Societal impact for patients with psoriasis: A nationwide Swedish register study. JAAD International 3, pages 63-75.
Crossref
Crossref
Yan Lu, Yi Xiao, Ming-Zhu Yin, Xing-Chen Zhou, Li-Sha Wu, Wang-Qing Chen, Yan Luo, Ye-Hong Kuang & Wu Zhu. (2021) Polyethylene Glycol Ointment Alleviates Psoriasis-Like Inflammation Through Down-Regulating the Function of Th17 Cells and MDSCs. Frontiers in Medicine 7.
Crossref
Crossref
A. A. Kubanov & E. E. Bogdanova. (2020) Epidemiology of psoriasis among the elderly population and volume of specialized medical care provided to patients with psoriasis in the Russian Federation in 2010–2019. Vestnik dermatologii i venerologii 96:5, pages 7-18.
Crossref
Crossref
A. A. Kubanov & E. E. Bogdanova. (2020) Epidemiology of psoriasis among the elderly population and volume of specialized medical care provided to patients with psoriasis in the Russian Federation in 2010–2019. Vestnik dermatologii i venerologii 96:5, pages 7-18.
Crossref
Crossref
Celine Miyazaki, Rosarin Sruamsiri, Jӧrg Mahlich & Wonjoo Jung. (2020) Treatment patterns and healthcare resource utilization in palmoplantar pustulosis patients in Japan: A claims database study. PLOS ONE 15:5, pages e0232738.
Crossref
Crossref
Maria Luca, Maria L. Musumeci, Federico Bardazzi, Concetta Potenza, Nicoletta Bernardini, Francesca Ferrara, Alessandra Pavone & Giuseppe Micali. (2020) Biologic agents perception in patients attending for the first-time to psoriasis centers: a multicenter Italian survey. Giornale Italiano di Dermatologia e Venereologia 155:2.
Crossref
Crossref
Ana M. Martins, Andreia Ascenso, Helena M. Ribeiro & Joana Marto. (2020) The Brain–Skin Connection and the Pathogenesis of Psoriasis: A Review with a Focus on the Serotonergic System. Cells 9:4, pages 796.
Crossref
Crossref
Giovanni Damiani, Alessia Pacifico, Dennis M. Linder, Paolo D.M. Pigatto, Rosalynn Conic, Ayman Grada & Nicola L. Bragazzi. (2019) Nanodermatology‐based solutions for psoriasis: State‐of‐the art and future prospects. Dermatologic Therapy 32:6.
Crossref
Crossref
James E. Frampton. (2019) Tildrakizumab: A Review in Moderate-to-Severe Plaque Psoriasis. American Journal of Clinical Dermatology 20:2, pages 295-306.
Crossref
Crossref
Daniel C. Baumgart, Laurent Misery, Sue Naeyaert & Peter C. Taylor. (2019) Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities?. Frontiers in Pharmacology 10.
Crossref
Crossref
Giovanni Damiani, Rosalynn R. Z. Conic, Valerio de Vita, Antonio Costanzo, Roberto Regazzini, Paolo D. M. Pigatto, Nicola L. Bragazzi, Alessia Pacifico & Piergiorgio Malagoli. (2018) When IL‐17 inhibitors fail: Real‐life evidence to switch from secukinumab to adalimumab or ustekinumab. Dermatologic Therapy 32:2, pages e12793.
Crossref
Crossref
L.M. Sawyer, L. Cornic, L.Å. Levin, C. Gibbons, A.H. Møller & G.B. Jemec. (2019) Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response. Journal of the European Academy of Dermatology and Venereology 33:2, pages 355-366.
Crossref
Crossref
Henry J. Grantham & Nick J. Reynolds. (2019)
The devil is in the data: differences in drug persistence between
SNIIRAM
, the French national health insurance database, and psoriasis biologics intervention registers
. British Journal of Dermatology 180:1, pages 8-10.
Crossref
Crossref
R.B. Warren, A. Halliday, C.N. Graham, I. Gilloteau, L. Miles & D. McBride. (2018) Secukinumab significantly reduces psoriasis-related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom. Journal of the European Academy of Dermatology and Venereology 32:12, pages 2178-2184.
Crossref
Crossref
M.M. Balp, S. Khalil, H. Tian, S. Gabriel, J. Vietri & T. Zuberbier. (2018) Burden of chronic urticaria relative to psoriasis in five European countries. Journal of the European Academy of Dermatology and Venereology 32:2, pages 282-290.
Crossref
Crossref
Haiming Chen, Huazhen Liu, Chuanjian Lu, Maojie Wang, Xiong Li, Hui Zhao, Yuhong Yan, Wanling Yu, Ling Han & Zhenhua Dai. (2018) PSORI-CM02 Formula Increases CD4+ Foxp3+ Regulatory T Cell Frequency and Ameliorates Imiquimod-Induced Psoriasis in Mice. Frontiers in Immunology 8.
Crossref
Crossref
D. Jungen, M. Augustin, A. Langenbruch, N. Zander, K. Reich, K. Strömer, D. Thaci, S. Purwins, M. Radtke & M. Gutknecht. (2017) Cost‐of‐illness of psoriasis – results of a German cross‐sectional study. Journal of the European Academy of Dermatology and Venereology 32:1, pages 174-180.
Crossref
Crossref
Ingrid Snekvik, Catherine H. Smith, Tom I.L. Nilsen, Sinéad M. Langan, Ellen H. Modalsli, Pål R. Romundstad & Marit Saunes. (2017) Obesity, Waist Circumference, Weight Change, and Risk of Incident Psoriasis: Prospective Data from the HUNT Study. Journal of Investigative Dermatology 137:12, pages 2484-2490.
Crossref
Crossref
R. Burgos-Pol, J.M. Martínez-Sesmero, J.M. Ventura-Cerdá, I. Elías, M.T. Caloto & M.Á. Casado. (2016) The Cost of Psoriasis and Psoriatic Arthritis in 5 European Countries: A Systematic Review. Actas Dermo-Sifiliográficas (English Edition) 107:7, pages 577-590.
Crossref
Crossref
R. Burgos-Pol, J.M. Martínez-Sesmero, J.M. Ventura-Cerdá, I. Elías, M.T. Caloto & M.Á. Casado. (2016) Coste de la psoriasis y artritis psoriásica en cinco países de Europa: una revisión sistemática. Actas Dermo-Sifiliográficas 107:7, pages 577-590.
Crossref
Crossref
Jalpa A. Doshi, Junko Takeshita, Lionel Pinto, Penxiang Li, Xinyan Yu, Preethi Rao, Hema N. Viswanathan & Joel M. Gelfand. (2016) Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population. Journal of the American Academy of Dermatology 74:6, pages 1057-1065.e4.
Crossref
Crossref
Lorenzo Mantovani, Massimo Medaglia, Patrizio Piacentini, Marcella Tricca, Gino Antonio Vena, Antonietta Vozza, Gabriella Castellino & Alessandro Roccia. (2016) Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective. Dermatology and Therapy 6:2, pages 151-167.
Crossref
Crossref
Keyou Li, Wenhua Yang, Zhe Li, Wangwang Jia, Jiazhou Li, Pengfei Zhang & Tiancun Xiao. (2016) Bitter apricot essential oil induces apoptosis of human HaCaT keratinocytes. International Immunopharmacology 34, pages 189-198.
Crossref
Crossref
Sofia Löfvendahl, Ingemar F. Petersson, Elke Theander, Åke Svensson, Caddie Zhou & Katarina Steen Carlsson. (2016) Incremental Costs for Psoriasis and Psoriatic Arthritis in a Population-based Cohort in Southern Sweden: Is It All Psoriasis-attributable Morbidity?. The Journal of Rheumatology 43:3, pages 640-647.
Crossref
Crossref
William R Swindell, Mrinal K Sarkar, Philip E Stuart, John J Voorhees, James T Elder, Andrew Johnston & Johann E Gudjonsson. (2015)
Psoriasis drug development and GWAS interpretation through
in silico
analysis of transcription factor binding sites
. Clinical and Translational Medicine 4:1.
Crossref
Crossref
Junko Takeshita, Joel M. Gelfand, Penxiang Li, Lionel Pinto, Xinyan Yu, Preethi Rao, Hema N. Viswanathan & Jalpa A. Doshi. (2015) Psoriasis in the US Medicare Population: Prevalence, Treatment, and Factors Associated with Biologic Use. Journal of Investigative Dermatology 135:12, pages 2955-2963.
Crossref
Crossref
F. Rencz, L. Kemény, J.Z. Gajdácsi, W. Owczarek, P. Arenberger, G.S. Tiplica, A. Stanimirović, M. Niewada, G. Petrova, L.T. Marinov, M. Péntek, V. Brodszky & L. Gulácsi. (2015) Use of biologics for psoriasis in Central and Eastern European countries. Journal of the European Academy of Dermatology and Venereology 29:11, pages 2222-2230.
Crossref
Crossref
J. Thomas, C. K. Narkowicz, G. A. Jacobson & G. M. Peterson. (2015) Safety and efficacy of kunzea oil-containing formulations for the management of psoriasis: a randomized, controlled trial. Journal of Clinical Pharmacy and Therapeutics 40:5, pages 566-572.
Crossref
Crossref